close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

2.230 +0.010 (+0.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
News headline image
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Invivyd ↗
 
Via Benzinga
News headline image
Invivyd: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Preview: Invivyd ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
News headline image
Earnings Scheduled For August 10, 2023 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
News headline image
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People ↗
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal  
Via Benzinga
News headline image
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
News headline image
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19 ↗
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal  
Via Benzinga
News headline image
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:IVVD Long Term Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc. ↗
San Diego, CA -- (SBWIRE) -- 05/25/2023 -- An investigation was announced on behalf of investors in shares of Invivyd, Inc. (NASDAQ:IVVD) over possible breaches of fiduciary duties by certain directors... 
Via SBWire
News headline image
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga
News headline image
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
News headline image
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
From Invivyd
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today